Our 2017

c. 17 million patients treated in >150 hospitals
>70,000 births attended and assisted

>320,000 dialysis patients treated
>48 million treatments carried out in >3,700 dialysis clinics

>273,000 employees in >100 countries at year-end
>90 lower-cost IV generic drugs launched

>€500 million invested in research & development
>€1.8 billion invested in hospitals and plants

Services provided to >670 hospitals
11 additional local medical care centers in Germany opened
Outstanding business year 2017

14th consecutive record year

More than €30 billion in sales for first time

Integration of Quirónsalud proceeding to plan

NxStage acquisition strengthens position in home dialysis

Successful entry into biosimilars market

Continued strong growth expected
Another year of strong sales and earnings growth

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2017</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>€m</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>29,471</td>
<td>33,886</td>
<td>+16%</td>
</tr>
<tr>
<td>EBIT</td>
<td>€m</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4,302</td>
<td>4,890</td>
<td>+15%</td>
</tr>
<tr>
<td>Net income</td>
<td>€m</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1,560</td>
<td>1,859</td>
<td>+21%</td>
</tr>
</tbody>
</table>

Constant currency growth rates, net income and EBIT adjusted and before special items
14th consecutive record year

Sales (in €bn)

CAGR 12%

Net income (in €m)

CAGR 22%

Net income before special items
A steadily growing Fresenius workforce

As of March 31, 2018

275,674
Employees worldwide

114,181

169,324

273,249


Annual General Meeting | May 18, 2018 | © Fresenius SE & Co. KGaA
25th consecutive dividend increase proposed

CAGR +16%
Termination of merger agreement with Akorn
Fresenius Helios: Europe’s leading hospital group

- 156 hospitals
- 41,000 beds
- 17 million patients
- 106,000 employees

In 2017
Fresenius Kabi: Strong growth in all areas

- >90 new IV generics
- >1 billion infusion solutions
- €428 million in investments
- About 70 production sites

In 2017
Fresenius Medical Care: World’s largest dialysis provider

- **about 140 million dialyzers**
- **>3,700 dialysis clinics**
- **>48 million treatments**
- **>320,000 patients**

In 2017
Fresenius Vamed: Full-service provider, active worldwide

Order intake >€1 billion

Services for >670 hospitals

>800 projects since founding

in >80 countries

In 2017
On the way to value-based healthcare
Group outlook 2018: Solid sales and earnings growth

<table>
<thead>
<tr>
<th>Sales growth</th>
<th>constant currency</th>
<th>5 - 8%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net income growth</td>
<td>constant currency</td>
<td>6 - 9%</td>
</tr>
<tr>
<td>Net income growth (excluding biosimilars)</td>
<td>constant currency</td>
<td>approx. 10 - 13%</td>
</tr>
</tbody>
</table>
Ambitious mid-term targets confirmed

Sales

<table>
<thead>
<tr>
<th>Year</th>
<th>CAGR</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>7.1%</td>
</tr>
<tr>
<td>2020</td>
<td>10.3%</td>
</tr>
</tbody>
</table>

Net income

<table>
<thead>
<tr>
<th>Year</th>
<th>CAGR</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>8.3%</td>
</tr>
<tr>
<td>2020</td>
<td>10.5%</td>
</tr>
</tbody>
</table>

CAGR; excl. strategic acquisitions; at February 2017 exchange rates and according to IFRS
Signposts for the next decade

Entry into biosimilars

Expansion of home dialysis

Internationalization of Fresenius Helios

Investments in production facilities
Our commitment: Better medicine for more people
Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.
Annual General Meeting – Fresenius SE & Co. KGaA

May 18, 2018 | Frankfurt